BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: Results of the LEOPOLD Kids Trial

Haemophilia

Volumn 22, Issue 3, 2016, Pages 354-360

  Ljung, R ^a   Kenet, G ^b   Mancuso, M E ^c   Kaleva, V ^d   Rusen, L ^e   Tseneklidou Stoeter, D ^f   Michaels, L A ^g   Shah, A ^g   Hong, W ^g   Maas Enriquez, M ^f   Kaleva, Valeria ^h   Stoyanova Deleva, Angelina ^h   Blanchette, Victor ^h   Dower, Nancy ^h   Clausen, Niels ^h   Kardos, Maria ^h   Kiss, Csongor ^h   Zombori, Marianna ^h   Nolan, Beatrice ^h   Kenet, Gili ^h   Santagostino, Elena ^h   Zanon, Ezio ^h   Luciani, Matteo ^h   Kovalova, Zhanna ^h   Rageliene, Lina ^h   Dobaczewski, Grzegorz ^h   Klukowska, Anna ^h   Mlynarkski, Wojciech ^h   Serban, Margit ^h   Rusen, Luminita ^h   Uscatescu, Valentina ^h   Kerlin, Bryce ^h   Ahuja, Sanjay ^h   Gruppo, Ralph ^h   Singleton, Tammuella ^h   more..

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b TEL AVIV UNIVERSITY   (Israel)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^e SC SANADOR SRL   (Romania)

^f BAYER PHARMA AG   (Germany)

^g BAYER CORPORATION   (United States)

^h NONE   (United States)

Author keywords

Children; Clinical trial; Factor VIII; Haemophilia A; Prophylaxis

Indexed keywords

BAY 81 8973; BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; COAGULATING AGENT; F8 PROTEIN, HUMAN;

AGE DISTRIBUTION; ANNUALIZED BLEEDING RATE; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CHILD; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EFFICACY PARAMETERS; HEMARTHROSIS; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSAL BLEEDING; MULTICENTER STUDY (TOPIC); OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SCHOOL CHILD; SIDE EFFECT; SKIN BLEEDING; SPONTANEOUS BLEEDING; TRAUMATIC BLEEDING; CLINICAL TRIAL; HALF LIFE TIME; HEMORRHAGE; INFANT; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; COAGULANTS; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFANT; MALE; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84949977266     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12866     Document Type: Article

References (7)

1. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arth-ropathy. J Thromb Haemost 2010; 8: 1895-902.
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
3. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document #179. Available at http://www.hemophilia.org/sites/default/files/document/files/masac179.pdf. Accessed April 24, 2015.
4. Vogel JH, Huesslein A, Goudar C, Severs J, Garger S, Bamberger T, et al. BAY 81-8973 - a new full-length recombinant FVIII product-using novel manufacturing technologies. Haemophilia 2010; 16: 40.
5. Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M. Prophylaxis versus on-demand treatment with BAY 81-8973, a full-length plasma-protein-free rFVIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015; 13: 360-9.
6. Fischer K, Collins P, Bjorkman S, Blanchette V, Oh M, Fritsch S, et al. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia 2011; 17: 433-8.
7. Saxena K, Lalezari S, Oldenburg J, Delesen H, Shah A, Tseneklidou-Stoeter D, et al. Pharmacokinetics, efficacy, and safety of BAY 81-8973, a full-length plasma-protein-free recombinant factor VIII product: results from the LEOPOLD trial. J Thromb Haemost 2013; 11: 928.